Highlights in Hematologic Malignancy Treatments: Leukemia, Myelodysplastic Syndromes, and Allotransplant-New Drugs on the Horizon for Acute Myeloid Leukemia.

JAMA Oncol

Division of Hematology/Oncology, Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, New York, New York2New York-Presbyterian Hospital/Columbia University Medical Center, New York, New York.

Published: March 2017

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.3928DOI Listing

Publication Analysis

Top Keywords

highlights hematologic
4
hematologic malignancy
4
malignancy treatments
4
treatments leukemia
4
leukemia myelodysplastic
4
myelodysplastic syndromes
4
syndromes allotransplant-new
4
allotransplant-new drugs
4
drugs horizon
4
horizon acute
4

Similar Publications

Background: Patients with haematologic malignancies are at increased risk of developing skin cancer and often experience worse skin cancer-related outcomes. However, there is a lack of nationwide, population-based data with long-term follow-up on the incidence and risks of different skin cancer types across all haematologic malignancies.

Objectives: To assess population-based risk estimates for cutaneous squamous cell carcinoma (CSCC), malignant melanoma (MM), Merkel cell carcinoma (MCC), and basal cell carcinoma (BCC) among patients with haematologic malignancies, stratified by skin cancer type and haematologic malignancy subgroup.

View Article and Find Full Text PDF

Targeting Protein-Protein Interactions in Hematologic Malignancies.

Annu Rev Pathol

January 2025

Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA; email:

Over the last two decades, there have been extensive efforts to develop small-molecule inhibitors of protein-protein interactions (PPIs) as novel therapeutics for cancer, including hematologic malignancies. Despite the numerous challenges associated with developing PPI inhibitors, a significant number of them have advanced to clinical studies in hematologic patients in recent years. The US Food and Drug Administration approval of the very first PPI inhibitor, venetoclax, demonstrated the real clinical value of blocking protein-protein interfaces.

View Article and Find Full Text PDF

Unlabelled: Spondyloenchondrodysplasia (SPENCD) is a rare genetic disorder characterized with skeletal dysplasia, immune dysregulation, and neurological impairment. Patients diagnosed with SPENCD at a single pediatric hematology center were included in the study. The patients' clinical characteristics, symptoms at presentation, imaging and laboratory results, and genetic analysis results were collected retrospectively from their files.

View Article and Find Full Text PDF

Purposes: This study aimed to determine the prevalence of Theileria equi (T. equi) and Babesia caballi (B. caballi) in racing horses in Erbil Province, Iraq, and to assess the associated hemato-biochemical changes in infected animals.

View Article and Find Full Text PDF

Congenital infantile brainstem high-grade gliomas (HGGs) are extremely rare. Given the limited literature characterizing this disease, management of these tumors remains challenging. Brainstem HGGs are generally associated with extremely poor prognosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!